Pharmigene, Inc. (TPEX:7595)

Market Cap	353.26M -39.1%
Revenue (ttm)	187.88M +25.9%
Net Income	-52.27M
EPS	-1.04
Shares Out	50.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,030
Open	7.35
Previous Close	7.35
Day's Range	7.35 - 7.36
52-Week Range	5.90 - 14.10
Beta	0.00
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Pharmigene

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers contract development and manufacturing organization; molecular diagnostic reagents; testing products, including pharmacogenomics, targeted therapy for cancer, disease risk assessment, and functional medicine services. In addition, it sells various platform, such as single-cell analysis platform / spatial gene expression; single-cell and spatial transcriptomics data analysis software; expert in mapping genomic structural variatio...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2005
• Employees: 42
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7595

Financial Performance

In 2025, Pharmigene's revenue was 199.89 million, an increase of 71.53% compared to the previous year's 116.53 million. Losses were -73.00 million, -11.91% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error